REV-ERB raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-11. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
=== Ethnopharmacological Perspectives === The Journal of Ethnopharmacology provides extensive documentation of insect based treatments in indigenous medicine. Ethnopharmacological research has revealed that insects are integral to traditional healing systems in many cultures. In South America ant and wasp venoms are used in pain management and inflammation control. Also in India scorpions and centipedes have been incorporated into Ayurvedic medicine for treating neurological disorders. These case studies illustrate the cultural diversity in insect based medicine and underscore the potential for modern pharmacological applications.
The enyzme cyclises nicotinamide adenine dinucleotide (a cation) to give initially nicotinamide and cyclic ADP-ribose as intermediate. The latter is then hydrolyzed to adenosine diphosphate ribose (ADP-ribose). This makes it different from NAD+ glycohydrolase (EC 3.2.2.5), where the hydrolysis gives ADP-ribose directly. The enzyme was characterised from beef spleen. The enzyme is also present in bacteria and humans. This enzyme is a hydrolase, specifically a glycosylase that hydrolyses N-glycosyl compounds. Other names of this enzyme include nicotinamide adenine dinucleotide (phosphate) nucleosidase, triphosphopyridine nucleotidase, NAD(P) nucleosidase, NAD(P)ase, and nicotinamide adenine dinucleotide (phosphate) glycohydrolase.
=== Amyloid formation === Although ELPs generally form reversible spherical aggregates due to their proline and glycine content, there is a possibility that, under certain conditions such as exceedingly high temperatures, ELPs will form amyloids, or irreversible aggregates of insoluble protein. It is also believed that changes in the ELP backbone leading to a reduction in the proline and glycine content may lead to ELPs with a greater propensity for the amyloid state. As amyloids are implicated in the progression of Alzheimer's disease as well as in prion-based diseases, such as Creutzfeldt-Jakob disease (CJD), modeling of ELP amyloid formation may be useful from a biomedical standpoint.
Spinal cord stimulation is a form of invasive neuromodulation therapy in common use since the 1980s. Its principal use is as a reversible, non-pharmacological therapy for chronic pain management that delivers mild electrical pulses to the spinal cord. In patients who experience pain reduction of 50 percent or more during a temporary trial, a permanent implant may be offered in which, as with a cardiac pacemaker, an implantable pulse generator about the size of a stopwatch is placed under the skin on the trunk. It delivers mild impulses along slender electrical leads leading to small electrical contacts, about the size of a grain of rice, at the area of the spine to be stimulated. Stimulation is typically in the 20–200 Hz range, though a novel class of stimulation parameters are now emerging that employ a 10 kHz stimulation train as well as 500 Hz "burst stimulation". Kilohertz stimulation trains have been applied to both the spinal cord proper as well as the dorsal root ganglion in humans. All forms of spinal cord stimulation have demonstrated varying degrees of efficacy in treating a variety of pharmacoresistant neuropathic or mixed (neuropathic and nociceptive) pain syndromes, such as post-laminectomy syndrome, low back pain, complex regional pain syndrome, peripheral neuropathy, peripheral vascular disease, and angina. The general process for spinal cord stimulation involves a temporary trailing of appropriate patients with an external pulse generator attached to epidural electrodes located in the lower thoracic spinal cord.
Sources: en.wikipedia.org
A malignant peripheral nerve sheath tumor (MPNST) is a form of cancer of the connective tissue surrounding peripheral nerves. Given its origin and behavior it is classified as a sarcoma. Neurofibromatosis type 1 (NF-1) is a risk factor for developing MPNSTs. The lifetime risk for an MPNST in patients with NF-1 is 8–13%. MPNST with rhabdomyoblastomatous component are called malignant triton tumors. The first-line treatment is surgical resection with wide margins. Chemotherapy and often radiotherapy are done as adjuvant and/or neoadjuvant treatment depending upon various risk factors.
Amino acid dating or racemization dating is a dating technique used to estimate the age of a specimen in paleobiology, molecular paleontology, archaeology, forensic science, taphonomy, sedimentary geology and other fields. This technique relates changes in amino acid molecules to the time elapsed since they were formed.
== Guinea == Karamokho Alfa – Religious leader who led a jihad that led to the formation of Futa Jallon, Guinea Ibrahim Sori Mawdo (The Elder) – Religious leader and Second Almaami of Futa Jalon, Guinea Abdul Rahman Ibrahima Sori - was a Fulani prince and Amir, from Fouta Djallon, in modern-day Guinea, West Africa, who was captured and sold to European slave traders, causing him to be enslaved in Mississippi, U.S, for 40 years. Bokar Biro – last independent Almamy of Fuuta Jalon, Resistance hero to French invasion, Guinea Thierno Aliou – Author, Muslim theologian and politician, Guinea Yacine Diallo – Politician. former member of French National Assembly, Guinea Boubacar Diallo Telli – Diplomat and politician. First Secretary-General of the Organization of African Unity (OAU), UN Representative, Ambassador to USA, Minister of Justice, Guinea Binta Pilote - Guinea armed forces pilot, first black female helicopter pilot in Africa. Aminata Diallo (military) - Second Brigadier-General Guinea Armed forces. Amadou Oury Bah (In French) - Prime Minister Guinea Saifoulaye Diallo - former foreign minister, former president of the National Assembly. Aïcha Bah Diallo - former Guinean education minister and women's rights activist. Mariama Wax Sylla (in french) - Former World Bank Group Resident Representative for Namibia, former minister of Agriculture, Minister of the Economy, Finance and Budget, Guinea.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.